{"Clinical Trial ID": "NCT01516736", "Intervention": ["INTERVENTION 1:", "LA-EP2006", "During each chemotherapy cycle, eligible patients receive LA-EP2006 s.c. after the application of chemotherapy.", "LA-EP2006: Eligible patients should receive six cycles of chemotherapy every three weeks. During each cycle of LA-EP2006 chemotherapy is injected s.c. after the application of chemotherapy.", "INTERVENTION 2:", "- Neulasta\u00ae", "During each chemotherapy cycle, eligible patients receive Neulasta\u00ae s.c. after the application of chemotherapy.", "Neulasta\u00ae: Eligible patients should receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle, pegfilgrastim is injected s.c. after the application of chemotherapy."], "Eligibility": ["Incorporation criteria:", "Breast cancer proven by histology", "\u2022 Eligibility for six cycles of neoadjuvant or adjuvant chemotherapy", "- Exclusion criteria:", "Concomitant or anterior chemotherapy for breast cancer", "- Simultaneous or anterior anticancer treatment for breast cancer, such as endocrine treatment, immunotherapy, monoclonal antibodies and/or biological treatment", "\u2022 Concomitant prophylactic antibiotics", "Previous treatment with any G-CSF product (stimulating factor of the granulocyte column)", "Other inclusion/exclusion criteria defined by the Protocol may apply."], "Results": ["Performance measures:", "Average duration of severe neutropenia (SDN) during chemotherapy cycle 1", "Average duration of severe neutropenia, defined as the number of consecutive days with ANC <0.5 \u00d7 10^9/l (grade 4 neutropenia).", "Time limit: 21 days (Cycle 1 of chemotherapy treatment)", "Results 1:", "Title of arm/group: LA-EP2006", "Description of the arm/group: During each chemotherapy cycle, eligible patients receive an LA-EP2006 s.c. post-chemotherapy application.", "LA-EP2006: Eligible patients should receive six cycles of chemotherapy every three weeks. During each cycle of LA-EP2006 chemotherapy is injected s.c. after the application of chemotherapy.", "Total number of participants analysed: 155", "Average (standard deviation)", "Unit of measure: FAS days: 151 participants", "1.36 (1.133)", "PP: 148 participants", "1.34 (1.141)", "Results 2:", "Title of the arm/group: Neulasta", "Description of the arm/group: During each chemotherapy cycle, eligible patients receive a post-chemotherapy application for Neulasta s.c.", "Neulasta: Eligible patients are programmed to receive six cycles of chemotherapy every three weeks. During each cycle of chemotherapy pegfilgrastim is injected s.c. post-chemotherapy application.", "Total number of participants analysed: 153", "Average (standard deviation)", "Unit of measure: FAS days: 149 participants", "1.19 (0.984)", "PP: 144 participants", "1.19 (0.991)"], "Adverse Events": ["Undesirable Events 1:", "Total: 29/155 (18.71 per cent)", "- Febrile neutropenia 16/155 (10.32 per cent)", "Neutropenia 4/155 (2.58 per cent)", "Thrombocytopenia 1/155 (0.65%)", "Anemia 1/155 (0.65%)", "Atrial fibrillation 0/155 (0.00 %)", "Cardiac arrest 1/155 (0.65%)", "1/155 (0.65%)", "Pericardial haemorrhage 1/155 (0.65%)", "Ocular irritation 0/155 (0.00 %)", "Abdominal pain 3/155 (1.94%)", "Adverse Events 2:", "Total: 32/153 (20.92 per cent)", "19/153 (12.42 per cent)", "Neutropenia 6/153 (3.92%)", "Thrombocytopenia 1/153 (0.65%)", "Anemia 0/153 (0.00 %)", "Atrial fibrillation 1/153 (0.65%)", "Cardiac arrest 0/153 (0.00 %)", "- Cardiorespiratory arrest 0/153 (0.00 %)", "Pericardial haemorrhage 0/153 (0.00 per cent)", "1/153 (0.65%)", "Abdominal pain 5/153 (3.27%)"]}